Home
ivps4
2017-06-16T21:39:52+00:00
News Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Sep 18, 2020Subjects in the Cytisinicline Arm Were 55% More Likely to Quit Smoking at 6 Months Compared to Subjects Who Received Varenicline
-
Sep 18, 2020Provides Mechanistic Rationale for the Clinical Findings that Cytisinicline (Cytisine) Treatment is Associated with Lower Rates of Nausea and Vomiting compared to Chantix
-
Apr 24, 2019Topline data from ORCA-1 trial expected in the Second Quarter of 2019
-
Apr 2, 2019Topline data from ORCA-1 trial expected in the Second Quarter of 2019
-
Feb 20, 2019Topline data from ORCA-1 trial expected in mid-2019
-
Sep 18, 2018Cytisine Demonstrated Superior Abstinence Rates Compared to Nicotine Replacement Therapy
-
Oct 30, 2017Company invites individual and institutional investors and advisors to attend virtualinvestorconferences.com
-
Oct 4, 2017Rapid Progress on Advancing Clinical Program with Commencement of Pharmacokinetic (PK) & Pharmacodynamic (PD) Cytisine Study and Completion of Enrollment in Food Effect PK Study
-
Jun 13, 2017Special Meeting of OncoGenex Stockholders to Vote on Proposed Merger Scheduled for August 1, 2017
-
Mar 8, 2017Professor Nancy Rigotti, MD, will chair a symposium entitled "Cytisine Update: Moving Research Forward Toward a Globally Affordable Tobacco Cessation Medication"
-
Mar 1, 2017Ongoing IND-enabling Non-clinical Program to Support the Use of Cytisine in Smoking Cessation
-
Jan 5, 2017Proposed Merger Will Create Clinical-Stage, Biopharmaceutical Company Focused on the Development and Commercialization of Cytisine for Smoking Cessation
Stock Info